TranspariMED clinical trial transparency

21 May 2017

The University of Aberdeen has pledged to conduct a review after an investigation revealed that the results of its medical research often remain inaccessible to doctors and patients. The investigation by TranspariMED, a Bristol-based initiative advocating for more transparency in medical research, shows that at least 20 clinical trials conducted at the university have not prere...

8 May 2017

New study documents how the lack of clinical trials transparency harms patients, taxpayers and investors, based on six in-depth case studies.

28 Mar 2017

The University of Aberdeen’s clinical trial policies require the summary results of some clinical trials to be posted on a registry within 12 months of trial end. However, the policy only covers some types of trials, and the university fails to assume responsibility for auditing staff compliance and publishing audit results.

Strengths:

Clear and time-bound results posting policy:

...

27 Mar 2017

What practical steps can the UK take to make evidence-based medicine a reality? How can we get all clinical trials registered and fully and accurately reported?

17 Mar 2017

The OECD has launched a consultation on access to innovative pharmaceuticals and sustainability of pharmaceutical spending.

The OECD seeks submissions that respond to one or more the following questions: 

  1. Reflecting on the last 5-10 years, what do you think have been the major changes affecting access to medicines?

  2. What are the top three issues that must be addressed to...

16 Mar 2017

Britain’s National Institute for Health Research (NIHR) has the strongest policies to reduce research waste, an assessment of major health funding agencies worldwide has found.

On the positive side, all funding agencies covered require registration of clinical trials before recruitment of patients. In contrast, “only six of the 11 funding agencies are explicit that they require...

16 Mar 2017

Clinical trials’ integrity and utility is routinely undermined by flaws in design, methods, publication and interpretation, a paper published in Trials concludes.

While the paper does not present new data, its summary of salient factors and the corresponding literature makes it a valuable point of departure for researchers and campaigners in the field of evidence-based medicine.

...

6 Mar 2017

What would it take to make unregistered or retrospectively registered clinical trials a thing of the past? In an opinion piece run by the BMJ in February 2017, Elizabeth Loder, its head of research, proposed treating unregistered trials as the research equivalent of medical ‘Never Events’, defined as “particularly shocking medical errors (such as wrong-site surgery) that should...

6 Mar 2017

The European Medicines Agency (EMA) in February 2017 launched a public consultation on the proposed revision to its policy on access to documents. The new version extends the scope of the EMA’s existing policy and includes new access rules for corporate documents held by the EMA, and new access rules for documents related to medicines for human and veterinary use held by the EM...

17 Feb 2017

Pharma-sponsored drug and device trial studies are about 30% more likely to have results and conclusions that favour the sponsor, a new Cochrane Library review has found.

The review found that studies run by pharma companies routinely show greater efficacy and less harms. The authors outlined some common ways in which sponsors can influence study outcomes, including the framing...

Please reload

Subscribe
Recent Posts
Please reload

This site was designed with the
.com
website builder. Create your website today.
Start Now